Bacopa Monnieri
NootropicThe medical score (74) is slightly above the community score (68), as clinical RCTs demonstrate consistent, albeit moderate, memory effects [s1, s2], while a considerable proportion of community users report adverse mood-blunting effects and absent efficacy [c1, c2, c3], reducing perceived utility.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Bacopa monnieri is among the best-evidenced herbal nootropics: a meta-analysis across 9 RCTs (n=518) shows consistent, moderate improvements in delayed word recall (d≈0.3–0.5) — but only after 8–12 weeks of use. Expect nothing sooner. A real issue underrepresented in clinical trials: a significant portion of the community reports motivational blunting and emotional anhedonia as reasons to quit. Always take with fat (bacosides are fat-soluble), and only use extracts tested for heavy metal contamination.
Description
Ayurvedic memory herb with well-documented effects on memory, attention, and anxiety reduction; acts via bacoside-mediated cholinergic and antioxidant mechanisms [s1, s2].
Bacopa monnieri (Brahmi) is a traditional medicinal plant from Ayurveda, documented in classical texts such as the Charaka Samhita and Sushruta Samhita for over 3,000 years as a so-called "Medhya Rasayana" (memory and intellect enhancer) [s12]. The primary active compounds are triterpenoid saponins referred to as bacosides (primarily Bacoside A and bacopasides) [s3]. The plant grows in moist tropical regions of South Asia and is available as a standardized extract (typically 45–55% bacoside content) or as whole-herb powder [s5]. Multiple randomized controlled clinical trials (RCTs) and a meta-analysis demonstrate improvements in delayed word recall, memory consolidation, and attention processing speed in healthy adults and older individuals [s1, s2, s4]. Effects typically onset only after 8–12 weeks of continuous use [s5, s6]. Clinical studies additionally show anxiolytic and mood-elevating effects, as well as reductions in cortisol levels under stress conditions [s7, s8]. Preliminary evidence from one RCT exists for children with ADHD-like symptoms [s9]. Quality concerns exist regarding heavy metal contamination (Cd, Pb, Cu, Zn) in some raw material batches; certified extracts (e.g., Bacognize®) have undergone safety assessments according to OECD guidelines [s13, s11].
Legal Status (DE)
In Germany, Bacopa monnieri is legally marketable as an over-the-counter food supplement (NEM) without requiring authorization as a medicinal product [s14]. The BfR recommends a maximum of 250 mg per day as a dietary supplement [s15]. Health claims for Bacopa monnieri have not been authorized by EFSA in the EU [s16].
Mechanism of Action
The effects of Bacopa monnieri are attributed to several complementary mechanisms [s3]: 1. Acetylcholinesterase inhibition: Bacosides (particularly Bacopaside X, quercetin, apigenin) inhibit the enzyme acetylcholinesterase (AChE), which is responsible for the degradation of acetylcholine (ACh). This increases synaptic ACh concentration, thereby promoting learning and memory formation [s3]. 2. Choline acetyltransferase activation: Simultaneously, ACh synthesis is enhanced through activation of choline acetyltransferase (ChAT) [s3]. 3. Antioxidant neuroprotection: Bacosides reduce oxidative stress in the brain via redox activation and enzyme induction. They protect neurons against H₂O₂-induced damage in vitro [s3]. 4. Beta-amyloid reduction: Animal study data demonstrate a reduction in beta-amyloid deposits, which is relevant for potential applications in neurodegenerative diseases [s3]. 5. Increased cerebral blood flow: Bacosides induce vasorelaxation in mesenteric arteries (dose-dependent, 0.1–100 µM), which may enhance cerebral perfusion [s3]. 6. Monoaminergic-serotonergic and dopaminergic modulation: Animal studies demonstrate normalization of stress-induced changes in corticosterone levels as well as noradrenaline, serotonin (5-HT), and dopamine (DA) in cortical and hippocampal tissue [s10]. 7. BDNF modulation: Evidence suggests elevation of brain-derived neurotrophic factor (BDNF), which is proposed to promote neuronal growth and cognitive flexibility [s6]. The lipophilic nature of bacosides means that bioavailability is improved when taken concomitantly with dietary fat [s5].
Dosing
Gedächtnisverbesserung und kognitive Leistung (Erwachsene)
- Dose
- 300–450 mg standardized extract (45–55% bacosides)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 12 Wochen (Mindestdauer für messbare Effekte)
- Timing
- With a high-fat meal (improves bioavailability)
- With food
- empfohlen
Ältere Erwachsene – Gedächtnis und Angstreduktion
- Dose
- 300–320 mg standardized extract (CDRI 08 / Synapsa)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 12–14 Wochen
- Timing
- With the main meal
- With food
- empfohlen
Stress- und Schlafmanagement
- Dose
- 150–300 mg standardized extract
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 6–8 Wochen
- Timing
- In the evening with a meal
- With food
- empfohlen
Kinder (ADHS-ähnliche Symptome, nur unter ärztlicher Aufsicht)
- Dose
- 225 mg CDRI 08® daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 14 Wochen
- Timing
- With a meal
- With food
- empfohlen
The BfR recommends a maximum of 250 mg per day as a dietary supplement in Germany [s15]. Clinical studies have used up to 600 mg/day without serious adverse events; however, doses above 450 mg have not been sufficiently investigated [s5].
Bacopa monnieri should always be taken with fat (e.g., with a meal), as bacosides are lipophilic and absorption is significantly improved thereby [s5]. Effects typically do not appear until after 8–12 weeks; immediate effects should not be expected [s2, s6].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (erhöhte Stuhlfrequenz, Übelkeit, Bauchkrämpfe) Most commonly reported side effect in clinical trials and community reports. Typically mild and transient, especially at the start of supplementation [s7, s13]. | häufig | leicht |
| Motivationsverlust / emotionale Abflachung (Anhedonie) A substantial proportion of the community reports loss of motivation and affective blunting; mechanistically possibly explained by serotonergic/dopaminergic modulation [c1, c2, c3]. | gelegentlich | moderat |
| Libidoverlust Mentioned repeatedly in community reports; no established clinical evidence, but plausible via monoaminergic mechanisms [c2]. | gelegentlich | leicht |
| Erhöhte Tagesmüdigkeit / Sedierung Occasionally reported, particularly at higher doses; possible GABAergic or serotonergic component [s8, c4]. | gelegentlich | leicht |
| Erhöhte Schilddrüsenhormonspiegel (T4) Bacopa monnieri may increase thyroid hormone production (T4). Clinically relevant in individuals on thyroid medication [s18]. | selten | moderat |
Contraindications
Bacopa may increase T4 levels, thereby potentiating or interfering with thyroid hormone activity. Use only under medical supervision [s18].
Insufficient safety data for pregnancy and lactation; use is not recommended [s13].
Bacopa inhibits acetylcholinesterase and may attenuate or reverse the effects of anticholinergic medications [s3, s18].
Caution is advised in cases of known allergy to botanically related plants [s13].
Contraindicated in uncontrolled hyperthyroidism due to potential T4-elevating effects [s18].
Interactions
Synergistic
Choline precursors supply the substrate for Bacopa-enhanced acetylcholine synthesis; frequently combined in nootropic stacks [c1, c5].
The combination is regarded by the nootropics community as synergistic for memory and neuronal plasticity; no clinical RCT available [c5].
Both adaptogenic herbs are frequently combined; evidence for additive stress-reducing and sleep-improving effects from traditional medicine and community experience [c4].
Bacopa inhibits acetylcholinesterase and enhances choline acetyltransferase activity, while citicoline increases acetylcholine production and provides neuroprotective agents. The combination may improve memory and learning more effectively than either supplement alone.
One study showed that the combination of Bacopa, phosphatidylserine, and choline synergistically protects the cholinergic system and more effectively buffers stress-induced neurotoxicity than the individual substances, suggesting an additive neuroprotective effect.
Fat-soluble co-factors such as omega-3 fatty acids may enhance absorption of Bacopa's active constituents (bacosides). Additionally, DHA promotes choline reuptake following acetylcholine hydrolysis, thereby supporting the cholinergic cycle.
Alpha-GPC provides highly bioavailable choline as a substrate for acetylcholine synthesis, while Bacopa inhibits acetylcholinesterase, slowing ACh degradation. The combination synergistically protects and prolongs cholinergic neurotransmission.
Ginseng and Bacopa are used in traditional medicine and in combination preparations to support memory, concentration, and cognitive performance. Both adaptogens may complement each other in their stress-protective and nootropic effects.
Antioxidants such as curcumin can complement the cellular protection provided by Bacopa's bacosides. Both substances exert neuroprotective effects via complementary antioxidant mechanisms.
Lion's Mane stimulates NGF (nerve growth factor) production via hericenones and erinacines, while Bacopa promotes dendritic growth and strengthens the cholinergic system. The combination may synergistically support neuroplasticity and memory.
Rhodiola Rosea acts primarily through rapid stress adaptation and energy enhancement, while Bacopa improves memory and cognitive function more long-term. The combination can synergistically cover both acute and chronic cognitive support.
Caution
Bacopa may increase T4 levels, thereby potentiating the effects of thyroid hormones; close monitoring of thyroid values required [s18].
Antagonistic effect: Bacopa increases ACh, anticholinergics block ACh receptors; mutual attenuation of effects possible [s3].
Theoretical interaction via platelet aggregation inhibition reported; clinical evidence limited; caution recommended [s18].
Bacopa may have blood glucose-lowering properties; risk of hypoglycemia should be considered when taken concomitantly with antidiabetic agents [s18].
Bacopa interacts with the serotonin and dopamine systems. Concomitant use with antidepressants may result in potentially synergistic effects or increased sedation. Combination should only be used under medical supervision.
Bacopa may increase GABA receptor density, thereby strongly potentiating the effects of other GABAergic substances. This can lead to excessive sedation and requires particular caution regarding dosing.
Studies
Tier A — High Evidence
Outcome: Cognition, particularly attention speed
Effect Size: Significant improvement in attention speed; moderate effect size
Outcome: CESD-10 depression, anxiety (combined), heart rate
Effect Size: Bacopa group showed reduction in depression and anxiety; placebo group showed increase
Outcome: Cognitive performance, mood, sleep (BacoMind®)
Effect Size: Significant improvement in cognitive performance, mood, and sleep vs. placebo after 14 weeks
Outcome: Stress management (PSS), sleep quality (PSQI)
Effect Size: Consistent, clinically meaningful improvements in subjective and objective outcomes
Outcome: Attention, hyperactivity, cognitive outcomes in boys aged 6–14 years
Effect Size: Improvements in cognitive outcomes; preliminary evidence
Outcome: Delayed word recall, memory consolidation
Effect Size: Consistent improvement in delayed recall across multiple studies
Tier B — Moderate Evidence
Outcome: Cognitive effects in children and adolescents, ADHD
Effect Size: Improvements in attention, cognition, and intelligence in polyherbal studies
Outcome: Overview of mechanisms and bioavailability
Effect Size: Summary of preclinical and clinical data; generally safe at standard doses
Tier C — Low Evidence
Outcome: AChE inhibition, neuroprotection mechanisms
Effect Size: Bacopaside X IC50 = 12.78 µM vs. donepezil IC50 = 0.0204 µM
Outcome: Corticosterone, monoamines (NA, 5-HT, DA) under stress
Effect Size: Normalization of stress-induced monoamine alterations in rat model
Outcome: Genotoxicity, subchronic toxicity (Bacognize®)
Effect Size: No toxicologically significant changes; no genotoxicity
Community Evidence
Top reported benefits
- Improvement of delayed memory recall after 8–12 weeks
- Reduced anxiety and inner restlessness
- Improved stress tolerance in daily life
- Improved sleep (particularly with evening administration)
- Increased cognitive endurance during mental work
Top reported issues
- Loss of motivation and emotional blunting (anhedonia) – frequently reported
- Gastrointestinal complaints (nausea, abdominal cramps, loose stools)
- Loss of libido
- Onset of effect highly delayed (>8 weeks) – many users discontinue beforehand
- No noticeable effect in a significant proportion of users
A significant portion of the r/Nootropics community describes a so-called "motivational blunting" effect and emotional blunting as a deal-breaker [c1, c2]. These effects are mechanistically attributed to serotonergic/dopaminergic modulation, but are poorly documented clinically [s10]. Quality variability from uncontrolled sources and heavy metal contamination in raw materials represent a real safety concern [s11, s13].
Scientific Sources
- Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract
Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al. (2014). Journal of EthnopharmacologyAPMID:24252493DOI - Effect of Bacopa monniera on stress induced changes in plasma corticosterone and brain monoamines in rats
Bhattacharya SK, Bhattacharya A, Kumar A, et al. (2007). PhytomedicineCPMID:17321089DOI - Safety evaluation of the genotoxicity and subchronic toxicity of standardized Bacopa extract (Bacognize®) from Bacopa monnieri
Muchhara J, Vachhani K, Dave S, et al. (2023). Journal of Applied Toxicology (SAGE)CDOI - Bacopa monnieri (Brahmi) – Benefits, Uses, Dosage & Ayurveda Guide
Ask-Ayurveda Editorial Team (2023). Ask-Ayurveda (non-peer-reviewed)DLink - Trace metals accumulation in Bacopa monnieri and their bioaccessibility
Bhattacharya P, Chatterjee D, Jacks G, et al. (2013). PubMedCPMID:23824547 - Fragen und Antworten zu Nahrungsergänzungsmitteln
BfR (Bundesinstitut für Risikobewertung) (2022). BfR Bundesinstitut für RisikobewertungALink - Bacopa Monnieri: Wirkung, Dosierung & Sicherheit – BfR-Empfehlung 250 mg
NahrungsHub Editorial Team (2023). nahrung-ergaenzungsmittel.de (non-peer-reviewed)DLink - EU register of health claims
European Commission (2024). European Commission – Food SafetyALink - Efficacy and Safety of Bacopa monnieri Extract for Stress Management and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial
Gavin Publishers Research Group (2024). Gavin Publishers (Journal of Complementary Medicine)BLink - Bacopa – Special Subjects (Dietary Supplements)
Merck Manuals Professional Editorial Team (2023). Merck Manual Professional EditionBLink - The Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review of Randomized, Controlled Human Clinical Trials
Pase MP, Kean J, Sarris J, et al. (2012). Journal of Alternative and Complementary MedicineAPMID:22747190DOI - Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research
Bhattacharya SK, Bhattacharya A, Kumar A, et al. (2023). PMC / Journal of EthnopharmacologyCLink - A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations
Katz M, Levine AA, Kol-Degani H, et al. (2016). Complementary Therapies in MedicineADOI - Bacopa Monnieri Dosage: How Much to Take?
NaturStack Editorial Team (2023). NaturStack (non-peer-reviewed)DLink - Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
Anbarasan S, Vijayakumar S, Prabhu D, et al. (2025). PubMed / Frontiers (PMC)BPMID:40507208 - Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial
Calabrese C, Gregory WL, Leo M, et al. (2008). Journal of Alternative and Complementary MedicineAPMID:18611150DOI - Einfluss von BacoMind® auf die geistige Leistungsfähigkeit von älteren Personen (RCT, Burgerstein Foundation)
Stough C, Lloyd J, Clarke J, et al. (2008). Burgerstein Foundation / NeuropsychopharmacologyBLink - Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial
Katz M, Levine AA, Kol-Degani H, et al. (2022). Phytotherapy ResearchAPMID:35041248DOI
Community Sources
Storage
Unopened
Store cool (15–25 °C), dry, and protected from light.
Opened
Keep container tightly closed; avoid moisture and heat. Use original packaging for capsule or tablet forms.
Notes
Standardized extracts (e.g., Bacognize®, BacoMind®) should be stored according to manufacturer specifications. Ensure heavy metal certification and third-party testing, as raw material batches may exhibit elevated Cd, Pb, Cu, and Zn levels [s11, s13].